FindTrial
Sign In

Clinical study of camrelizumab combined with apatinib and SOX regimen in first-line treatment of advanced gastric cancer

A prospective, single-center, single-arm clinical study of camrelizumab combined with apatinib and SOX regimen in first-line treatment of advanced gastric cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046429
Enrollment
Unknown
Registered
2021-05-15
Start date
2021-05-15
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Experimental group:Camrelizumab + apatinib + ticgio + oxaliplatin

Sponsors

The Second Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 85 years, no gender limit; 2. Patients with recurrence after gastrectomy or patients with advanced gastric cancer who have not received any previous treatment (negative HER-2); 3. ECOG PS score 0-2; 4. Expected survival >=6 months; 5. The main organs function normally, and there are no patients with serious functional abnormalities of blood, heart, lung, liver, kidney, bone marrow or immune deficiency. Laboratory tests meet the following requirements: (1) Hemoglobin (Hb) >=90 g/L; (2) WBC >=3.0x10^9/L; Neutrophil count (NEUT) >=1.5x10^9/L; (3) Platelet (PLT) >=100x10^9/L; (4) Liver function (AST or ALT) <=2.5 ULN; Renal function (serum creatinine SCR) level <=1.5 ULN; (5) Total bilirubin (TBIL) <=1.5 ULN; (6) Urinary protein and urinary occult blood < 2+; Fecal occult blood < 2+. 6. Patients voluntarily participate in this study, sign informed consent, good compliance, and cooperate with follow-up; 7. Researchers believe there are benefits to treatment.

Exclusion criteria

Exclusion criteria: 1. Patients who have been confirmed to be allergic to the test drug and/or its excipients; 2. Patients who have received or are receiving additional chemotherapy, radiotherapy, targeted or immunotherapy; 3. Pregnant or breastfeeding women; 4. According to the judgment of the investigator, patients who are not suitable for inclusion in this study; 5. Patients who test positive for Her-2 and are willing to receive treatment with Herceptin; 6. Patients who have medical systemic diseases and psychiatric diseases that are not suitable for chemotherapy; 7. Patients who have acute infection and need antibiotic treatment; 8. Patients who have participated in other drug clinical trials within four weeks.

Design outcomes

Primary

MeasureTime frame
progression-free survival;—

Countries

China

Contacts

Public ContactCheng Yunsheng

The Second Affiliated Hospital of Anhui Medical University

305331653@qq.com+86 13721062265

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026